Mersana Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
09/05/2024 14:31
* Mersana Therapeutics Inc MRSN.OQ reported a quarterly
adjusted
loss of 16 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -52 cents. The mean expectation of
eight analysts for the quarter was for a loss of 18 cents per
share. Wall Street expected results to range from -21 cents
to -13 cents per share.
* Revenue rose 18.5% to $9.25 million from a year ago;
analysts
expected $8.50 million.
* Mersana Therapeutics Inc's reported EPS for the quarter
was a
loss of 16 cents.
* The company reported a quarterly loss of $19.31 million.
* Mersana Therapeutics Inc shares had fallen by 24.1% this
quarter and gained 46.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 8% in
the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Mersana
Therapeutics Inc is $7.00
This summary was machine generated from LSEG data May 9 at 01:30
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.18 -0.16 Beat
Dec. 31 2023 -0.16 -0.16 Met
Sep. 30 2023 -0.36 -0.27 Beat
Jun. 30 2023 -0.44 -0.47 Missed